2018-11-29
Large
0personInquired
0personFavorited
ConnectType:
T - Technology & Patents
Industry:
Pharmaceuticals and Chemical Intermediates
Country / Region:
China
Company Type:
Other
Registered Capital:
RMB 32.401066 million
Company Capability: Process Technology Development、Chemical Technology & Patents
Yichang Eastsun Biochemical Pharmaceutical Co., Ltd. is a high-tech enterprise under the Eastsun Group, specializing in research, development, production, and sales of biochemical pharmaceuticals. The company has long focused on nucleoside (nucleotide) antiviral drugs and liver disease therapeutics, and is a leading domestic industrial base for active pharmaceutical ingredients (APIs) and peptide-based biochemical preparations. Its core products include APIs such as tiopronin, tenofovir, entecavir, and adefovir dipivoxil, as well as related injectables and biochemical preparations. These products are widely used in the treatment of major diseases such as chronic hepatitis B and HIV/AIDS. Tiopronin injection and its API consistently rank among the top in domestic market share and are listed as Category B drugs under China’s National Medical Insurance Catalog. Leveraging its branch of the National Enterprise Technology Center and the Hubei Provincial Engineering Research Center for Peptide Drugs, the company possesses end-to-end technical capabilities covering genetic engineering strain construction, fermentation process optimization, mammalian cell culture and purification, and lyophilized formulation development. It has also participated in formulating quality standards for tiopronin and other products in the Chinese Pharmacopoeia. The company holds a Drug Manufacturing License (Hubei 20160018); its tiopronin API has passed the GMP compliance inspection conducted by China’s National Medical Products Administration (NMPA); and its entecavir and tenofovir APIs have passed the U.S. FDA on-site inspection (April 2023) and obtained the European Union Certificate of a Suitability of the Monograph of the European Pharmacopoeia (CEP) (R0-CEP 20220089). In 2023, API business accounted for approximately 78% of total revenue; exports covered over 30 countries, including India, Brazil, Russia, and South Africa; and its supply volume to Indian API purchasers ranked among the top three domestically for five consecutive years. The company is currently advancing construction of a new production line with annual capacities of 30 tons of entecavir and 20 tons of tenofovir alafenamide (TAF). Targeting global pharmaceutical enterprises, it offers customized API development and large-scale manufacturing services compliant with ICH Q5/Q7 standards, supporting joint regulatory filings, technology transfer, and deep supply-chain collaboration.
Connect
More Suppliers科林能源技术(北京)有限公司
77
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp
凯铭科技(杭州)有限公司
79
0
T - Technology & Patents
P - Procurement
Dalian Pace Gas Equipment Co., Ltd.
112
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp





































